Page 4 - Genentech News Today

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support...

Vir Biotechnology, Inc. announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer , effective June 03, 2024. Dr. Eisner will be a part of...

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.

TOKYO, May 28, 2024 - (JCN Newswire) - Hitachi High-Tech Corporation announced that Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration.

JATT Acquisition (NYSE:JATT – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Institutional & Insider Ownership 48.0% of JATT Acquisition […]

JATT Acquisition (NYSE:JATT – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Valuation & Earnings This table compares JATT Acquisition […]

News and commentary from the endocrinology world

A discussion with the former CEO of the Bill & Melinda Gates Foundation